Roche single-dose flu med finds success for people at high risk of complications

Jul 17, 2018

Roche has announced that a late-stage study showed baloxavir marboxil, its new Tamiflu replacement, reduced symptoms in people at high risk of complications. The company found that the drug showed superior efficacy in speeding up improvement of symptoms versus a placebo.

The drug showed only modest benefits compared to Tamiflu in previously published studies.

The latest trial focused on adults at least 65 years old or patients with asthma, chronic lung disease, diabetes or heart disease.

U.S. regulators have accelerated their review and could make a decision by Dec. 24.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments